Cosentyx (secukinumab) / Novartis - LARVOL DELTA

Improvement of treatment resistant facial discoid dermatosis with secukinumab. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology

Intestinal homeostasis alteration toward mucosal inflammation with blocking IL-17 in psoriasis patients: a case series. (PubMed, Transl Gastroenterol Hepatol) - "The median age was 64 years, the disease duration was 31 years, two were female, four received secukinumab, and one received brodalumab. Proteobacteria was increased after the administration. Although no one occurred clinical symptoms after IL-17 inhibition in this case series, blocking IL-17 signals altered intestinal homeostasis toward mucosal inflammation."

Journal • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Psoriasis • IL17A

RASL for Reduction of Scapho-Lunate Dissociation (AAOS 2026) - "This video depicts the case presentation and surgical technique for treatment of SL dissociation with RASL screw placement. We highlight different approaches and relevant anatomy."

Orthopedics

SEGMENTAL STIFF SKIN SYNDROME: A MULTICENTER RETROSPECTIVE STUDY OF 26 PEDIATRIC PATIENTS (WRMC 2026) - "Systemic therapies including methotrexate (n=8), prednisone (n=8), mycophenolate mofetil (n=9), and losartan (n=9) yielded little benefit. This study, one of the largest SegSSS cohort study to date, expands the clinical and histologic understanding of this rare disorder. Findings highlight frequent misdiagnosis, limited therapeutic efficacy, and novel observations, including inflammatory infiltrates on biopsy and secukinumab responsiveness independent of IL-17 mutations."

Retrospective data • CNS Disorders • Dermatology • Fibrosis • Pediatrics • Rare Diseases • Rheumatology • IL17A

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I study. (PubMed, Expert Opin Investig Drugs) - P1 | "Generalizability may be limited beyond Asian males. The study is registered at Clinicaltrials.gov (NCT07054970)."

Clinical • First-in-human • Journal • P1 data • PK/PD data

Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. (CMS Press Release) - "The selected drug list for the third cycle of negotiations is: Anoro Ellipta...Botox; Botox Cosmetic; Cimzia; Cosentyx; Entyvio...Orencia...Trulicity....Xeljanz; Xeljanz XR; Xolair."

Medicare • Allergy • Ankylosing Spondylitis • Asthma • Chronic Obstructive Pulmonary Disease • Crohn's disease • Idiopathic Arthritis • Immunology • Migraine • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Trans-scapho-perilunate dislocation and Gilula's arcs. (PubMed, Rev Esp Sanid Penit) - No abstract available

Journal

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL-23 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time-point being considered. At 16 weeks, for PSSI-100, ixekizumab 150 mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16 weeks, for Sc-PGA 0/1 bimekizumab 320 mg every 4 weeks ranked highest; at 8 weeks, for PSSI-100 ixekizumab 80 mg every 2 weeks ranked highest; at 8 weeks, for Sc-PGA 0/1 secukinumab 300 mg at weeks 1, 2, 3 and then every 4 weeks ranked highest. Small-molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision-making."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis. (PubMed, JAMA Dermatol) - "Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review. (PubMed, Mediterr J Rheumatol) - "Uveitis exposure-adjusted incidence rates per 100 patient years (EAIR/100PY) ranged between 0-4.5 for tumour necrosis factor inhibitors (TNFi), 0.5-3.9 for interleukin-17 inhibitors (IL-17i) and 0.8-3.3 for upadacitinib (UPA), as derived from available RCTs. Evidence from non-RCTs, reporting uveitis incidence rates per 100PY, ranged between 3.46-55.2 for etanercept, 1.38-15.7 for adalimumab, 1.82-25.9 for infliximab, 1.39-6.8 for golimumab, 0-9.4 for secukinumab and 0 for ixekizumab...IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

p16-mediated G0/G1 cell cycle arrest leads to SASP and fibrosis in Fuchs endothelial corneal dystrophy. (PubMed, Cell Death Dis) - "Additionally, multiplex analysis to detect senescence-associated secretory phenotype (SASP) after chronic exposure revealed significant upregulation of pathogenic factors such as IL-8 and IL-17, which were attenuated by SB225002 (anti-CXCR2) and secukinumab (anti-IL-17A). Senolytic cocktail of Dasatinib and Quercetin treatment alleviated fibrosis by selectively eliminating senescent cells and improved the survival of healthy cells. This study introduces a novel in vitro model of FECD, revealing the crucial role of cell cycle modulation, senescence and interleukins in the disease advancement and pathogenesis. The findings suggest that targeting senescence and cytokine-driven inflammation could be a promising therapeutic strategy for mitigating FECD progression."

Journal • Fibrosis • Immunology • Inflammation • Ophthalmology • Transplantation • CXCL8 • CXCR2 • IL17A

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab. (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2025 ➔ Sep 2026 | Trial primary completion date: Nov 2025 ➔ Sep 2026

HEOR • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China. (PubMed, Inflamm Res) - "Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics."

Journal • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report. (PubMed, SAGE Open Med Case Rep) - "She achieved disease control after transitioning to secukinumab, an interleukin-17 inhibitor. This case highlights the importance of early monitoring for paradoxical reactions in patients with severe psoriasis after initiating tumor necrosis factor-alpha inhibitor therapy and the value of transitioning to an alternative biologic class for effective management."

Journal • Dermatology • Immunology • Oncology • Psoriasis • Pustular Psoriasis • IL17A

SPINK5 variants drive clinical variability in Netherton syndrome through Th2/Th17 skewing and influence therapeutic outcomes. (PubMed, J Allergy Clin Immunol Pract) - "The described findings support the concept of indirect immune dysregulation in NS due to a defective skin barrier, emphasizing the need for therapies that extend beyond single cytokine or receptor blockade."

IO biomarker • Journal • Dermatology • Dermatopathology • Genetic Disorders • Immunology • Pediatrics • Primary Immunodeficiency • Pruritus • CD4 • IFNG • IL17A • PD-1

Infection risk among psoriasis biologic-new users: a cohort study on the French National Health Data System. (PubMed, J Am Acad Dermatol) - "Biologics are associated with low overall infection risks. Among biologics, ustekinumab and IL-23 inhibitors show the lowest overall risk (time to the first inpatient/outpatient event)."

Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • IL23A

The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis. (PubMed, Mediterr J Rheumatol) - "Conducting a search through PubMed/MEDLINE, Scopus, and Web of Science, using keywords and Medical Subject Headings (MeSH) terms such as "spondyloarthritis", "psoriatic arthritis", "IL-17A", "IL-17F", "IL-23", "IL-23 independent mechanisms", "dual inhibition", "pathogenesis", "gut-joint axis", "secukinumab", "ixekizumab", "bimekizumab", "sonelokimab", we select the relevant literature for this comprehensive pathophysiological narrative...Inhibiting both IL-17A and IL-17F signifies not only a significant therapeutic advancement but also a vital strategy towards overcoming the limitations of our current armamentarium in achieving deeper and more sustained remission in SpA. Future studies and long-term data will be essential in determining the position of dual IL-17A/F inhibitors within treatment guidelines."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A • IL23A

Clinical outcomes of scaphocapitate fusion using single headless cannulated screw following lunate excision in advanced-stage Kienböck disease. (PubMed, J Orthop Surg (Hong Kong)) - "One patient (4.2%) reported mild screw irritation without surgical intervention; no other complications occurred.ConclusionSingle-screw scapho-capitate fusion and lunate excision can be considered a suitable treatment option for advanced Kienböck's disease, offering pain reduction, positive effects on functional recovery, acceptable healing rates, and a low risk of complications. However, larger, prospective studies are needed to demonstrate the long-term results of this method and its comparative effectiveness with other surgical techniques."

Clinical data • Journal • Retrospective data • Pain

National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and/or MRI evidence (flcube.com) - "Clinical Basis: Global Phase III PREVENT study....Next Steps: Commercial launch expected Q2 2026..."

China approval • Launch non-US • Immunology • Spondylarthritis

Hidradenitis suppurativa and psoriasis. Therapeutic response to secukinumab (PubMed, Medicina (B Aires)) - "We report the case of a 47-year-old woman diagnosed with hidradenitis suppurativa who developed psoriasis lesions over time. After receiving multiple therapeutic regimens without response, she began treatment with secukinumab, with excellent outcomes for both entities."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Psoriasis • IL17A

Net sales grew +8% (cc1, +8% USD) with core operating income up +14% (cc, +12% USD) (GlobeNewswire) - "Sales growth driven by continued strong performance from priority brands including...Kesimpta (+36% cc)...Cosentyx (+8% cc)...Kesimpta (USD 1 228 million, +27% cc) sales grew across all regions driven by increased demand and strong access...Cosentyx (USD 1 807 million, +11% cc) sales grew across all regions, driven by volume, with continued demand for recent launches (including HS and IV in the US) and steady performance in core indications (PsO, PsA, AS and nr-AxSpA)...Leqvio (USD 335 million, +46% cc) continued steady growth across all regions...Fabhalta (USD 155 million, +167% cc) sales grew, reflecting continued launch execution in PNH as well as renal indications IgAN and C3G."

Sales • Ankylosing Spondylitis • Familial Hypercholesterolemia • Heterozygous Familial Hypercholesterolemia • Hidradenitis Suppurativa • Multiple Sclerosis • Paroxysmal Nocturnal Hemoglobinuria • Psoriasis • Psoriatic Arthritis

Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation. (PubMed, Afr Health Sci) - "The total effective rate in the study group (83.33% vs. 60.00%) was higher than that in the control group. Secukinumab along with phosphodiesterase 4 inhibitors reduces p38MAPK activation, and improves immune response, inflammation, and clinical symptoms in patients with psoriasis."

Journal • Retrospective data • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • IL6

Cosentyx: Regulatory submission in US/EU/Japan for polymyalgia rheumatica in H1 2026 (Novartis) - Q4 & FY2025 Results: Regulatory approval in US for polymyalgia rheumatica in H2 2026

EMA filing • FDA approval • FDA filing • Japan filing • Immunology